CSIMarket
 
Bristol myers Squibb Company  (BMY)
Other Ticker:  
 
 
Price: $51.5900 $-0.75 -1.433%
Day's High: $52.7 Week Perf: -5.17 %
Day's Low: $ 51.62 30 Day Perf: 4.35 %
Volume (M): 1,007 52 Wk High: $ 71.07
Volume (M$): $ 52,068 52 Wk Avg: $58.53
Open: $52.32 52 Wk Low: $47.58



 Market Capitalization (Millions $) 107,256
 Shares Outstanding (Millions) 2,079
 Employees 32,200
 Revenues (TTM) (Millions $) 45,006
 Net Income (TTM) (Millions $) 8,040
 Cash Flow (TTM) (Millions $) 2,194
 Capital Exp. (TTM) (Millions $) 1,209

Bristol Myers Squibb Company
Bristol-Myers Squibb Company was incorporated under the laws of the State of Delaware in August 1933 under the name Bristol-Myers Company, as successor to a New York business started in 1887. In 1989, Bristol-Myers Company changed its name to Bristol-Myers Squibb Company as a result of a merger. The Company, through its divisions and subsidiaries, is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceuticals and other healthcare related products.

The Company has four reportable segments'Pharmaceuticals, Oncology Therapeutics Network (OTN), Nutritionals and Other Healthcare. The Pharmaceuticals segment is made up of the global pharmaceutical and international (excluding Japan) consumer medicines business. The OTN segment provides oncology products, supportive care products and related supplies to office-based oncologists in the United States. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula business. The Other Healthcare segment consists of ConvaTec, Medical Imaging and Consumer Medicines (North America and Japan) businesses.

In the Company's Pharmaceuticals segment and in its ConvaTec and Medical Imaging businesses, the Company promotes its products in medical journals and directly to health care providers such as doctors, nurse practitioners, physician assistants, pharmacists, hospitals, Pharmacy Benefit Managers (PBMs), Managed Care Organizations (MCOs) and government agencies. The Company also markets directly to consumers in the United States through direct-to-consumer print, radio and television advertising.

The Company's operations include several pharmaceutical sales organizations. Each sales organization markets a distinct group of products and is typically based on particular therapeutic areas or physician groups. These sales organizations often focus on selling new products when they are introduced, and marketing to physicians is increasingly targeted at specialists and high value primary care physicians.

The Company's prescription pharmaceutical products are sold principally to wholesalers, but the Company also sells directly to retailers, hospitals, clinics, government agencies and pharmacies.'Pharmaceutical wholesalers in the United States are;'McKesson Corporation (McKesson), Cardinal and AmerisourceBergen Corporation.

Competition

The markets in which Bristol-Myers Squibb competes are generally broad-based and highly competitive. The principal means of competition vary among product categories and business groups.

The Company's Pharmaceuticals segment competes with other worldwide research-based drug companies, many smaller research companies with more limited therapeutic focus and generic drug manufacturers. Important competitive factors include product efficacy, safety and ease of use, price and demonstrated cost-effectiveness, marketing effectiveness, product labeling, service and research and development of new products and processes. Sales of the Company's products can be impacted by new studies that indicate a competitor's product has greater efficacy for treating a disease or particular form of disease than one of the Company's products.



   Company Address: Route 206 & Province Line Road Princeton 8543 NJ
   Company Phone Number: 252-4621   Stock Exchange / Ticker: NYSE BMY
   


Customers Net Income fell by BMY's Customers Net Profit Margin fell to

-11.5 %

2.66 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABBV   -1.34%    
ABT   -6.89%    
JNJ   -3.67%    
LLY        1.02% 
MRK   -0.99%    
PFE   -1.04%    
• View Complete Report
   



Business Update

Bristol Myers Squibb's Tender Offer for RayzeBio Expires Amid Challenges in Supplier Revenues and Cost of Sales

Published Fri, Feb 23 2024 11:59 AM UTC

Bristol Myers Squibb, a leading global biopharmaceutical company, has announced that its tender offer to acquire all outstanding shares of RayzeBio, Inc. has expired. The company's decision comes as it faces challenges in its supplier revenues and an increase in the cost of sales. This article aims to ly analyze the facts surrounding these developments.1. Bristol Myers Squib...

Bristol Myers Squibb Company

Breaking News: Bristol Myers Squibb Sets the Stage for Remarkable Financial Growth, Surging Revenue by a Remarkable 0.622%

Bristol Myers Squibb (BMY), a leading player in the Major Pharmaceutical Preparations sector, recently announced the completion of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or the HSR Act, in relation to its tender offer to acquire all outstanding shares of RayzeBio, Inc. (RYZB) for a total cash price of $4.1 billion. This milestone marks an important step in the merger process between the two companies and underscores their shared vision for the future.
BMY has established itself as a major player in the industry with over 2,073,118,279.5699 million shares outstanding. Currently, the company's stock is being traded at $49.7525, reflecting its stability and potential for growth. Despite some challenges in their recent financial report, BMY remains a promising investment option.

Merger and Acquisition

Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period in Pursuit of Transformative Merger in the Oncology Sector.

Published Mon, Feb 12 2024 11:59 AM UTC

PRINCETON, N.J. & SAN DIEGO - Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) jointly declared today the culmination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, also known as the HSR Act, in relation to Bristol Myers Squibb's previously disclosed tender offer to procure all of the exceptional shares of RayzeBio com...

Merger and Acquisition

Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio

Published Tue, Jan 23 2024 1:30 PM UTC

Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Princeton, New Jersey - Bristol Myers Squibb (NYSE: BMY) has recently announced the successful completion of its acquisition of Mirati Therapeutics, Inc. (Mirati), marking a significant milestone in the company's efforts to expand and enhance its oncology ...

Product Service News

Revolutionary Partnership in Cancer Treatment: Bristol Myers Squibb Collaborates with SystImmune to Bring Promising Therapy to Patients

Published Mon, Dec 11 2023 9:15 PM UTC

SystImmune and Bristol Myers Squibb Form Global Partnership for Innovative Cancer Treatment
In a groundbreaking collaboration, clinical-stage biopharmaceutical company SystImmune and Bristol Myers Squibb (BMY) have joined forces to develop and commercialize BL-B01D1, a potentially revolutionary EGFRxHER3 bispecific antibody-drug conjugate (ADC). This strategic partnersh...






 

Bristol Myers Squibb's Segments
 
Eliquis
 Segment     of total Revenue
SPRYCEL
 Segment     of total Revenue
ABILIFY
 Segment     of total Revenue
Erbitux
 Segment     of total Revenue
SUSTIVA
 Segment     of total Revenue
BARACLUDE
 Segment     of total Revenue
ORENCIA
 Segment     of total Revenue
Other
 Segment     of total Revenue
Total Pharmaceuticals
 Segment     of total Revenue
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Bristol Myers Squibb announced annual revenue outlook on

Earnings Outlook
Bristol myers Squibb Company issued annual earnings guidance on

 
Geographic Revenue Dispersion
United States
EMEA
Other




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com